Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression Lucia Vráblová; Hana Klamová; Ivana Skoumalová; Jana Navrátilová; Romana Janská; Jan Grohmann; Milena Holzerová; Edgar Faber;

Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring Fernanda Salles Seguro; Carolina Maria Pinto Domingues Carvalho Silva; Carla Maria Boquimpani de Moura; Monika Conchon; Laura Fogliatto; Vaneuza Araujo Moreira Funke; André Abdo; Ariane Vieira Scarlatelli Macedo; Marilia Harumi Higushi dos Santos; José Francisco Kerr Saraiva;

Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies Tomasz Sacha; Katarzyna Krawczyk;